Neurocrine Biosciences, Inc. NBIX
Email when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
The news check keeps the assessment current.
General analysis — not personal advice.
A full position may be justified at current valuation given the commercial momentum.
Strong revenue growth, profitability and new pipeline progress support the hold signal despite the stock trading below prior highs.
The market reacts positively to pipeline diversification and commercial momentum around INGREZZA and CRENESSITY.
HOLD is the call. Positive is the market mood. Low risk means less can go wrong.
Latest change
- 3 Nov 2026 — Report shows strong growth driven by higher INGREZZA sales and completed Soleno acquisition.
About the company
Neurocrine Biosciences develops and commercializes medicines targeting neurological, psychiatric and endocrine disorders. The company has two commercial products INGREZZA and CRENESSITY and recently added VYKAT XR through the Soleno acquisition. Operations are profitable with strong growth and a late-stage pipeline.
Bull case
Strong Q3 report with 41 % revenue growth and raised Ingrezza guidance plus new pipeline additions create positive momentum.
Bear case
The stock trades below prior highs with elevated expectations priced in and limited news flow for the remainder of 2026.
Why this signal
Strong revenue growth, profitability and new pipeline progress support the hold signal despite the stock trading below prior highs.
Recent news
Neurocrine released its Q3 report on November 2 with revenue of $1.123 billion (+41 % YoY) and raised full-year Ingrezza guidance to $2.90–2.925 billion. The Soleno Therapeutics acquisition was completed during the quarter and CRENESSITY plus VYKAT XR showed strong sales growth.